Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension
In the event-driven FREEDOM-EV trial, oral treprostinil delayed clinical worsening in patients with pulmonary arterial hypertension (PAH). Open-label extension studies offer additional data about tolerability, efficacy, and survival, especially for those initially assigned placebo. The aim of the cu...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
Advances in therapy
Year: 2024, Jahrgang: 41, Heft: 2, Pages: 618–637 |
| ISSN: | 1865-8652 |
| DOI: | 10.1007/s12325-023-02711-x |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12325-023-02711-x
|
| Verfasserangaben: | Ekkehard Grünig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, Antoine Hage, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, Yang Yuanhua, Zaixin Yu, James Lordan, Linda Cadaret, Rob Grover, Aliou Ousmanou, Scott Seaman, Chunqin Deng, Meredith Broderick, R. James White, for the FREEDOM-EV Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1879850494 | ||
| 003 | DE-627 | ||
| 005 | 20240905102926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02711-x |2 doi | |
| 035 | |a (DE-627)1879850494 | ||
| 035 | |a (DE-599)KXP1879850494 | ||
| 035 | |a (OCoLC)1425200295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 245 | 1 | 0 | |a Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension |c Ekkehard Grünig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, Antoine Hage, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, Yang Yuanhua, Zaixin Yu, James Lordan, Linda Cadaret, Rob Grover, Aliou Ousmanou, Scott Seaman, Chunqin Deng, Meredith Broderick, R. James White, for the FREEDOM-EV Investigators |
| 264 | 1 | |c 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 20 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: December 6, 2023 | ||
| 500 | |a Gesehen am 02.02.2024 | ||
| 520 | |a In the event-driven FREEDOM-EV trial, oral treprostinil delayed clinical worsening in patients with pulmonary arterial hypertension (PAH). Open-label extension studies offer additional data about tolerability, efficacy, and survival, especially for those initially assigned placebo. The aim of the current study was to determine if oral treprostinil changed survival when considering the parent and extension study, if treprostinil provides functional benefits for participants initially assigned to placebo, and if the benefits observed for those treated with treprostinil were durable. | ||
| 650 | 4 | |a Clinical study | |
| 650 | 4 | |a Clinical worsening | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a COMPERA 2.0 | |
| 650 | 4 | |a Prostacyclin | |
| 650 | 4 | |a Pulmonary arterial hypertension | |
| 650 | 4 | |a REVEAL Lite 2 | |
| 650 | 4 | |a Risk status | |
| 700 | 1 | |a Rahaghi, Franck |e VerfasserIn |4 aut | |
| 700 | 1 | |a Elwing, Jean |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vizza, Carmine Dario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pepke-Zaba, Joanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shen, Jieyan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yao, Hua |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hage, Antoine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenkranz, Stephan |d 1966- |e VerfasserIn |0 (DE-588)115007814 |0 (DE-627)506349608 |0 (DE-576)289815894 |4 aut | |
| 700 | 1 | |a Vonk, Madelon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balasubramanian, Vijay |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yuanhua, Yang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yu, Zaixin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lordan, James |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cadaret, Linda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grover, Rob |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ousmanou, Aliou |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seaman, Scott |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deng, Chunqin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Broderick, Meredith |e VerfasserIn |4 aut | |
| 700 | 1 | |a White, R. James |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 41(2024), 2, Seite 618–637 |h Online-Ressource |w (DE-627)563170433 |w (DE-600)2421646-X |w (DE-576)306836041 |x 1865-8652 |7 nnas |a Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:2 |g pages:618–637 |g extent:20 |a Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s12325-023-02711-x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240202 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |e 50000PG112535801 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1879850494 |e 4474010574 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online veröffentlicht: December 6, 2023","Gesehen am 02.02.2024"],"recId":"1879850494","name":{"displayForm":["Ekkehard Grünig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, Antoine Hage, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, Yang Yuanhua, Zaixin Yu, James Lordan, Linda Cadaret, Rob Grover, Aliou Ousmanou, Scott Seaman, Chunqin Deng, Meredith Broderick, R. James White, for the FREEDOM-EV Investigators"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2421646-X"],"issn":["1865-8652"],"eki":["563170433"]},"language":["eng"],"origin":[{"publisherPlace":"Tarporley","dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisher":"Springer Healthcare Communications"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Advances in therapy","title":"Advances in therapy"}],"part":{"issue":"2","year":"2024","extent":"20","pages":"618–637","text":"41(2024), 2, Seite 618–637","volume":"41"},"disp":"Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extensionAdvances in therapy","recId":"563170433","pubHistory":["Nachgewiesen 17.2000 -"]}],"title":[{"title_sort":"Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension","title":"Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension"}],"person":[{"role":"aut","given":"Ekkehard","family":"Grünig","display":"Grünig, Ekkehard"},{"display":"Rahaghi, Franck","family":"Rahaghi","given":"Franck","role":"aut"},{"given":"Jean","display":"Elwing, Jean","family":"Elwing","role":"aut"},{"display":"Vizza, Carmine Dario","family":"Vizza","given":"Carmine Dario","role":"aut"},{"role":"aut","given":"Joanna","display":"Pepke-Zaba, Joanna","family":"Pepke-Zaba"},{"role":"aut","display":"Shen, Jieyan","family":"Shen","given":"Jieyan"},{"role":"aut","family":"Yao","display":"Yao, Hua","given":"Hua"},{"family":"Hage","display":"Hage, Antoine","given":"Antoine","role":"aut"},{"given":"Stephan","family":"Rosenkranz","display":"Rosenkranz, Stephan","role":"aut"},{"role":"aut","display":"Vonk, Madelon","family":"Vonk","given":"Madelon"},{"role":"aut","family":"Balasubramanian","display":"Balasubramanian, Vijay","given":"Vijay"},{"role":"aut","given":"Yang","family":"Yuanhua","display":"Yuanhua, Yang"},{"given":"Zaixin","display":"Yu, Zaixin","family":"Yu","role":"aut"},{"family":"Lordan","display":"Lordan, James","given":"James","role":"aut"},{"role":"aut","given":"Linda","family":"Cadaret","display":"Cadaret, Linda"},{"display":"Grover, Rob","family":"Grover","given":"Rob","role":"aut"},{"role":"aut","display":"Ousmanou, Aliou","family":"Ousmanou","given":"Aliou"},{"given":"Scott","family":"Seaman","display":"Seaman, Scott","role":"aut"},{"role":"aut","given":"Chunqin","display":"Deng, Chunqin","family":"Deng"},{"role":"aut","given":"Meredith","family":"Broderick","display":"Broderick, Meredith"},{"family":"White","display":"White, R. James","given":"R. James","role":"aut"}],"physDesc":[{"extent":"20 S.","noteIll":"Illustrationen"}],"origin":[{"dateIssuedDisp":"2024","dateIssuedKey":"2024"}],"language":["eng"],"id":{"eki":["1879850494"],"doi":["10.1007/s12325-023-02711-x"]},"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a GRUENIGEKKORALTREPRO2024 | ||